James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Biosciences ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Patricia Hurley, Joan Boren and Costantino Congiatu, PPD||June 2, 2015 More than $60 billion worth of patents on biological products are expiring before 2020, representing a major opportunity for the pharmaceutical industry.
Walt Berghahn , Healthcare Compliance Packaging Council (HCPC)||June 2, 2015 Spurred by several trends including the patent cliff, new product launches and changes in healthcare, the contract packaging market is looking at sustained growth in the years ahead
Tim Wright, Editor||May 6, 2015 Herein are the results of our 2015 Annual Outsourcing Survey, where we call on you, the readers, to help us benchmark the state of the pharmaceutical outsourcing industry.